Literature DB >> 20047149

Drug targeting: learning from toxin entry and trafficking in mammalian cells.

Robert A Spooner1, Peter Watson.   

Abstract

A significant number of therapeutic targets reside inside cells and intracellular organelles. Therapeutics therefore must be able to gain access to cellular compartments, and be able to interact specifically with a given molecule to exert a desired effect. Many naturally occurring toxins perform such targeting with apparent ease, making them excellent paradigms for the delivery of therapeutics to the cell interior. By studying the mechanisms of cell entry, trafficking and modes of toxicity of these model delivery vectors, researchers can decipher how cells transport both endogenous molecules and exogenously applied therapeutics inside cells. Perhaps more importantly, the exploitation of cell binding and trafficking motifs could allow a therapeutic to target specifically, traffic within and escape from cellular compartments; in addition, toxic domains can be used to disrupt cell function specifically for therapeutic purposes. This review provides an overview of recent developments in the understanding of toxin targeting and trafficking, and discusses how these developments could result in opportunities for the design of more specific and efficient systems for therapeutic targeting.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20047149

Source DB:  PubMed          Journal:  Curr Opin Drug Discov Devel        ISSN: 1367-6733


  4 in total

1.  Pulsed magneto-motive ultrasound imaging to detect intracellular trafficking of magnetic nanoparticles.

Authors:  Mohammad Mehrmohammadi; Min Qu; Li L Ma; Dwight K Romanovicz; Keith P Johnston; Konstantin V Sokolov; Stanislav Y Emelianov
Journal:  Nanotechnology       Date:  2011-09-16       Impact factor: 3.874

2.  The insulin receptor negatively regulates the action of Pseudomonas toxin-based immunotoxins and native Pseudomonas toxin.

Authors:  Xiu Fen Liu; David J FitzGerald; Ira Pastan
Journal:  Cancer Res       Date:  2013-01-24       Impact factor: 12.701

3.  Antitumor effects of immunotoxins are enhanced by lowering HCK or treatment with SRC kinase inhibitors.

Authors:  Xiu-Fen Liu; Laiman Xiang; David J FitzGerald; Ira Pastan
Journal:  Mol Cancer Ther       Date:  2013-10-21       Impact factor: 6.261

4.  ABMA, a small molecule that inhibits intracellular toxins and pathogens by interfering with late endosomal compartments.

Authors:  Yu Wu; Valérie Pons; Amélie Goudet; Laetitia Panigai; Annette Fischer; Jo-Ana Herweg; Sabrina Kali; Robert A Davey; Jérôme Laporte; Céline Bouclier; Rahima Yousfi; Céline Aubenque; Goulven Merer; Emilie Gobbo; Roman Lopez; Cynthia Gillet; Sandrine Cojean; Michel R Popoff; Pascal Clayette; Roger Le Grand; Claire Boulogne; Noël Tordo; Emmanuel Lemichez; Philippe M Loiseau; Thomas Rudel; Didier Sauvaire; Jean-Christophe Cintrat; Daniel Gillet; Julien Barbier
Journal:  Sci Rep       Date:  2017-11-14       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.